ArticleBioImpacts : BI2026
Enhanced anticancer efficacy of α-lipoic acid-loaded TPGS micelles: Synthesis, characterization, and evaluation in a 4T1 breast cancer model.
Article in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: α-Lipoic acid (ALA) is a potent antioxidant with anticancer properties, but its clinical application is limited by poor water solubility and low bioavailability. Current nanocarrier systems for ALA delivery suffer from low encapsulation efficiency, rapid drug release kinetics, and biocompatibility concerns that restrict their therapeutic potential. This study aimed to develop and evaluate ALA-loaded D-alpha-tocopheryl polyethylene glycol succinate (TPGS) micelles as an innovative nanomedicine platform to overcome existing limitations and enhance anticancer efficacy. Methods: ALA was loaded into TPGS micelles via modified solvent evaporation method and comprehensively characterized by TEM, DLS, and FTIR examination. Drug loading and encapsulation efficiency were quantitatively determined. Results: The formulation achieved superior encapsulation efficiency of 70%, with DLS analysis revealing micelles having mean diameter of 30-40 nm (polydispersity index: 0.234) and zeta potential of -1.9 mV. TEM confirmed spherical morphology. FTIR validated structural integrity with characteristic peaks. Conclusion: ALA-loaded TPGS micelles demonstrate enhanced anticancer efficacy through improved drug delivery, controlled release kinetics, and effective modulation of apoptotic pathways, supporting their potential for clinical translation in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.